Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alnylam Pharmaceuticals
Alnylam granted U.S. patent covering small interfering RNAs
August 18th, 2006
Alnylam Pharmaceuticals, Inc., (ALNY), a leading RNAi therapeutics company, announced that a new key fundamental patent from its exclusively held "Tuschl II" patent series was issued by the United States Patent and Trademark Office (USPTO). The newly issued U.S. patent (U.S. Patent No. 7,078,196 or " '196 patent") broadly covers methods of making small interfering RNAs (siRNAs), the molecules that mediate RNAi, and includes 79 claims covering chemical modifications needed to introduce "drug-like" properties in RNAi therapeutics. The issued patent is exclusively licensed to Alnylam for RNAi therapeutics on a worldwide basis through an agreement with Garching Innovation...
Source: Biotech Law Weekly (2006-08-18)
|
